Acquired antibodies to merozoite antigens in children from Uganda with uncomplicated or severe plasmodium falciparum malaria

Clinical and Vaccine Immunology

Volumn 20, Issue 8, 2013, Pages 1170-1180

  Ismail, Hodan Ahmed ^a   Ribacke, Ulf ^a,b   Reiling, Linda ^c   Normark, Johan ^a   Egwang, Tom ^d   Kironde, Fred ^d   Beeson, James G ^c   Wahlgren, Mats ^a   Persson, Kristina E M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BURNET INSTITUTE   (Australia)

^d MAKERERE UNIVERSITY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; ERYTHROCYTE BINDING ANTIGEN 140; ERYTHROCYTE BINDING ANTIGEN 175; ERYTHROCYTE BINDING ANTIGEN 181; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; PARASITE ANTIGEN; RETICULOCYTE BINDING PROTEIN HOMOLOGUE 2; RETICULOCYTE BINDING PROTEIN HOMOLOGUE 4; UNCLASSIFIED DRUG;

AGE; ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MEROZOITE; PARASITEMIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; UGANDA;

ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ANTIGENS, SURFACE; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFANT; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; SURFACE PLASMON RESONANCE; UGANDA;

EID: 84880887960     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00156-13     Document Type: Article

References (99)

1. Crompton PD, Pierce SK, Miller LH. 2010. Advances and challenges in malaria vaccine development. J. Clin. Invest. 120:4168-4178.
2. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434:214-217.
3. Harvey KL, Gilson PR, Crabb BS. 2012. A model for the progression of receptor-ligand interactions during erythrocyte invasion by Plasmodium falciparum. Int. J. Parasitol. 42:567-573.
4. Baum J, Maier AG, Good RT, Simpson KM, Cowman AF. 2005. Invasion by P. falciparum merozoites suggests a hierarchy of molecular interactions. PLoS Pathog. 1:e37. doi:10.1371/journal.ppat.0010037.
5. Cowman AF, Crabb BS. 2006. Invasion of red blood cells by malaria parasites. Cell 124:755-766.
6. Miller LH, Baruch DI, Marsh K, Doumbo OK. 2002. The pathogenic basis of malaria. Nature 415:673-679.
7. Persson KEM, McCallum FJ, Reiling L, Lister NA, Stubbs J, Cowman AF, Marsh K, Beeson JG. 2008. Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies. J. Clin. Invest. 118:342-351.
8. Kadekoppala M, Holder AA. 2010. Merozoite surface proteins of the malaria parasite: the MSP1 complex and the MSP7 family. Int. J. Parasitol. 40:1155-1161.
9. Low A, Chandrashekaran IR, Adda CG, Yao S, Sabo JK, Zhang X, Soetopo A, Anders RF, Norton RS. 2007. Merozoite surface protein 2 of Plasmodium falciparum: expression, structure, dynamics, and fibril formation of the conserved N-terminal domain. Biopolymers 87:12-22.
10. Adda CG, Murphy VJ, Sunde M, Waddington LJ, Schloegel J, Talbo GH, Vingas K, Kienzle V, Masciantonio R, Howlett GJ, Hodder AN, Foley M, Anders RF. 2009. Plasmodium falciparum merozoite surface protein 2 is unstructured and forms amyloid-like fibrils. Mol. Biochem. Parasitol. 166:159-171.
11. Tonhosolo R, Wunderlich G, Ferreira MU. 2001. Differential antibody recognition of four allelic variants of the merozoite surface protein-2 (MSP-2) of Plasmodium falciparum. J. Eukaryot. Microbiol. 48:556-564.
12. Hodder AN, Crewther PE, Anders RF. 2001. Specificity of the protective antibody response to apical membrane antigen 1. Infect. Immun. 69: 3286-3294.
13. Waters AP, Thomas AW, Deans JA, Mitchell GH, Hudson DE, Miller LH, McCutchan TF, Cohen S. 1990. A merozoite receptor protein from Plasmodium knowlesi is highly conserved and distributed throughout Plasmodium. J. Biol. Chem. 265:17974-17979.
14. Cortes A, Mellombo M, Masciantonio R, Murphy VJ, Reeder JC, Anders RF. 2005. Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1. Infect. Immun. 73:422-430.
15. Cortes A, Mellombo M, Mueller I, Benet A, Reeder JC, Anders RF. 2003. Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infect. Immun. 71:1416-1426.
16. Cohen S, McGregor IA, Carrington SC. 1961. Gamma-globulin and acquired immunity to human malaria. Nature 192:733-737.
17. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P. 1990. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J. Exp. Med. 172:1633-1641.
18. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, Chantavanich P, Foucault C, Chongsuphajaisiddhi T, Druilhe P. 1991. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am. J. Trop. Med. Hyg. 45:297-308.
19. Doolan DL, Dobano C, Baird JK. 2009. Acquired immunity to malaria. Clin. Microbiol. Rev. 22:13-36.
20. Branch OH, Udhayakumar V, Hightower AW, Oloo AJ, Hawley WA, Nahlen BL, Bloland PB, Kaslow DC, Lal AA. 1998. A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kilodalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. Am. J. Trop. Med. Hyg. 58:211-219.
21. Fowkes FJ, Richards JS, Simpson JA, Beeson JG. 2010. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis. PLoS Med. 7:e1000218. doi:10.1371/journal.pmed.1000218.
22. Dodoo D, Theander TG, Kurtzhals JA, Koram K, Riley E, Akanmori BD, Nkrumah FK, Hviid L. 1999. Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. Infect. Immun. 67:2131-2137.
23. Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, Kaslow DC, Holder AA, Riley EM. 1996. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J. Infect. Dis. 173: 765-769.
24. John CC, Moormann AM, Pregibon DC, Sumba PO, McHugh MM, Narum DL, Lanar DE, Schluchter MD, Kazura JW. 2005. Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. Am. J. Trop. Med. Hyg. 73:222-228.
25. Metzger WG, Okenu DM, Cavanagh DR, Robinson JV, Bojang KA, Weiss HA, McBride JS, Greenwood BM, Conway DJ. 2003. Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria. Parasite Immunol. 25:307-312.
26. Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma EC, Tiono AB, Konate AT, Chilengi R, Theisen M, Dodoo D, Remarque E, Bosomprah S, Milligan P, Sirima SB. 2008. Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Infect. Immun. 76:759-766.
27. Polley SD, Conway DJ, Cavanagh DR, McBride JS, Lowe BS, Williams TN, Mwangi TW, Marsh K. 2006. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine 24:4233-4246.
28. Polley SD, Mwangi T, Kocken CH, Thomas AW, Dutta S, Lanar DE, Remarque E, Ross A, Williams TN, Mwambingu G, Lowe B, Conway DJ, Marsh K. 2004. Human antibodies to recombinant protein constructs of Plasmodium falciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23:718-728.
29. Richards JS, Stanisic DI, Fowkes FJI, Tavul L, Dabod E, Thompson JK, Kumar S, Chitnis CE, Narum DL, Michon P, Siba PM, Cowman AF, Mueller I, Beeson JG. 2010. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin. Infect. Dis. 51:E50-E60.
30. Roussilhon C, Oeuvray C, Muller-Graf C, Tall A, Rogier C, Trape JF, Theisen M, Balde A, Perignon JL, Druilhe P. 2007. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med. 4:e320. doi:10.1371/journal.pmed.0040320.
31. Marsh K, Kinyanjui S. 2006. Immune effector mechanisms in malaria. Parasite Immunol. 28:51-60.
32. Cohen S, Butcher GA, Crandall RB. 1969. Action of malarial antibody in vitro. Nature 223:368-371.
33. Dent AE, Bergmann-Leitner ES, Wilson DW, Tisch DJ, Kimmel R, Vulule J, Sumba PO, Beeson JG, Angov E, Moormann AM, Kazura JW. 2008. Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults. PLoS One 3:e3557. doi:10.1371/journal.pone.0003557.
34. Egan AF, Burghaus P, Druilhe P, Holder AA, Riley EM. 1999. Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol. 21:133-139.
35. Marsh K, Otoo L, Hayes RJ, Carson DC, Greenwood BM. 1989. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans. R. Soc. Trop. Med. Hyg. 83:293-303.
36. McCallum FJ, Persson KEM, Mugyenyi CK, Fowkes FJ, Simpson JA, Richards JS, Williams TN, Marsh K, Beeson JG. 2008. Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS One 3:e3571. doi:10.1371/journal.pone.0003571.
37. Persson KEM, Lee CT, Marsh K, Beeson JG. 2006. Development and optimization of high-throughput methods to measure Plasmodium falciparum- specific growth inhibitory antibodies. J. Clin. Microbiol. 44:1665- 1673.
38. Crompton PD, Miura K, Traore B, Kayentao K, Ongoiba A, Weiss G, Doumbo S, Doumtabe D, Kone Y, Huang CY, Doumbo OK, Miller LH, Long CA, Pierce SK. 2010. In vitro growth-inhibitory activity and malaria risk in a cohort study in mali. Infect. Immun. 78:737-745.
39. Rono J, Färnert A, Olsson D, Osier F, Rooth I, Persson KEM. 2012. Plasmodium falciparum line-dependent association of in vitro growthinhibitory activity and risk of malaria. Infect. Immun. 80:1900-1908.
40. Richards JS, Stanisic DI, Fowkes FJ, Tavul L, Dabod E, Thompson JK, Kumar S, Chitnis CE, Narum DL, Michon P, Siba PM, Cowman AF, Mueller I, Beeson JG. 2010. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin. Infect. Dis. 51:e50-e60.
41. Pullen GR, Fitzgerald MG, Hosking CS. 1986. Antibody avidity determination by ELISA using thiocyanate elution. J. Immunol. Methods 86: 83-87.
42. Hearty S, Conroy PJ, Ayyar BV, Byrne B, O'Kennedy R. 2010. Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends. Expert Rev. Vaccines 9:645-664.
43. Igonet S, Vulliez-Le Normand B, Faure G, Riottot MM, Kocken CH, Thomas AW, Bentley GA. 2007. Cross-reactivity studies of an anti- Plasmodium vivax apical membrane antigen 1 monoclonal antibody: binding and structural characterisation. J. Mol. Biol. 366:1523-1537.
44. Plassmeyer ML, Reiter K, Shimp RL Jr, Kotova S, Smith PD, Hurt DE, House B, Zou X, Zhang Y, Hickman M, Uchime O, Herrera R, Nguyen V, Glen J, Lebowitz J, Jin AJ, Miller LH, MacDonald NJ, Wu Y, Narum DL. 2009. Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. J. Biol. Chem. 284:26951-26963.
45. Reddy SB, Anders RF, Beeson JG, Färnert A, Kironde F, Berenzon SK, Wahlgren M, Linse S, Persson KEM. 2012. High-affinity antibodies to Plasmodium falciparum merozoite antigens are associated with protection from malaria. PLoS One 7:e32242. doi:10.1371/journal.pone.0032242.
46. Akpogheneta OJ, Dunyo S, Pinder M, Conway DJ. 2010. Boosting antibody responses to Plasmodium falciparum merozoite antigens in children with highly seasonal exposure to infection. Parasite Immunol. 32: 296-304.
47. Arnot D. 1998. Unstable malaria in Sudan: the influence of the dry season. Clone multiplicity of Plasmodium falciparum infections in individuals exposed to variable levels of disease transmission. Trans. R. Soc. Trop. Med. Hyg. 92:580-585.
48. Babiker HA, Lines J, Hill WG, Walliker D. 1997. Population structure of Plasmodium falciparum in villages with different malaria endemicity in east Africa. Am. J. Trop. Med. Hyg. 56:141-147.
49. Babiker HA, Ranford-Cartwright LC, Currie D, Charlwood JD, Billingsley P, Teuscher T, Walliker D. 1994. Random mating in a natural population of the malaria parasite Plasmodium falciparum. Parasitology 109:413-421.
50. Bendixen M, Msangeni HA, Pedersen BV, Shayo D, Bodker R. 2001. Diversity of Plasmodium falciparum populations and complexity of infections in relation to transmission intensity and host age: a study from the Usambara Mountains, Tanzania. Trans. R. Soc. Trop. Med. Hyg. 95:143- 148.
51. Hoffmann EH, da Silveira LA, Tonhosolo R, Pereira FJ, Ribeiro WL, Tonon AP, Kawamoto F, Ferreira MU. 2001. Geographical patterns of allelic diversity in the Plasmodium falciparum malaria-vaccine candidate, merozoite surface protein-2. Ann. Trop. Med. Parasitol. 95:117-132.
52. Konate L, Zwetyenga J, Rogier C, Bischoff E, Fontenille D, Tall A, Spiegel A, Trape JF, Mercereau-Puijalon O. 1999. Variation of Plasmodium falciparum msp1 block 2 and msp2 allele prevalence and of infection complexity in two neighbouring Senegalese villages with different transmission conditions. Trans. R. Soc. Trop. Med. Hyg. 93(Suppl 1):21-28.
53. al-Yaman F, Genton B, Reeder JC, Anders RF, Smith T, Alpers MP. 1997. Reduced risk of clinical malaria in children infected with multiple clones of Plasmodium falciparum in a highly endemic area: a prospective community study. Trans. R. Soc. Trop. Med. Hyg. 91:602-605.
54. Bereczky S, Liljander A, Rooth I, Faraja L, Granath F, Montgomery SM, Färnert A. 2007. Multiclonal asymptomatic Plasmodium falciparum infections predict a reduced risk of malaria disease in a Tanzanian population. Microbes Infect. 9:103-110.
55. Branch OH, Takala S, Kariuki S, Nahlen BL, Kolczak M, Hawley W, Lal AA. 2001. Plasmodium falciparum genotypes, low complexity of infection, and resistance to subsequent malaria in participants in the Asembo Bay Cohort Project. Infect. Immun. 69:7783-7792.
56. Färnert A, Rooth I, Svensson Snounou G, Bjorkman A. 1999. Complexity of Plasmodium falciparum infections is consistent over time and protects against clinical disease in Tanzanian children. J. Infect. Dis. 179:989- 995.
57. Färnert A, Williams TN, Mwangi TW, Ehlin A, Fegan G, Macharia A, Lowe BS, Montgomery SM, Marsh K. 2009. Transmission-dependent tolerance to multiclonal Plasmodium falciparum infection. J. Infect. Dis. 200:1166-1175.
58. Mayor A, Saute F, Aponte JJ, Almeda J, Gomez-Olive FX, Dgedge M, Alonso PL. 2003. Plasmodium falciparum multiple infections in Mozambique, its relation to other malariological indices and to prospective risk of malaria morbidity. Trop. Med. Int. Health 8:3-11.
59. Muller DA, Charlwood JD, Felger I, Ferreira C, do Rosario V, Smith T. 2001. Prospective risk of morbidity in relation to multiplicity of infection with Plasmodium falciparum in Sao Tome. Acta Trop. 78:155-162.
60. Roper C, Richardson W, Elhassan IM, Giha H, Hviid L, Satti GM, Theander TG, Arnot DE. 1998. Seasonal changes in the Plasmodium falciparum population in individuals and their relationship to clinical malaria: a longitudinal study in a Sudanese village. Parasitology 116:501-510.
61. Normark J, Nilsson D, Ribacke U, Winter G, Moll K, Wheelock CE, Bayarugaba J, Kironde F, Egwang TG, Chen Q, Andersson B, Wahlgren M. 2007. PfEMP1-DBL1- amino acid motifs in severe disease states of Plasmodium falciparum malaria. Proc. Natl. Acad. Sci. U. S. A. 104:15835- 15840.
62. WHO. 2000. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans. R. Soc. Trop. Med. Hyg. 94(Suppl 1):S1-S90.
63. Okello PE, Van Bortel W, Byaruhanga AM, Correwyn A, Roelants P, Talisuna A, D'Alessandro U, Coosemans M. 2006. Variation in malaria transmission intensity in seven sites throughout Uganda. Am. J. Trop. Med. Hyg. 75:219-225.
64. Yeka A, Banek K, Bakyaita N, Staedke SG, Kamya MR, Talisuna A, Kironde F, Nsobya SL, Kilian A, Slater M, Reingold A, Rosenthal PJ, Wabwire-Mangen F, Dorsey G. 2005. Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Med. 2:e190. doi:10.1371/journal .pmed.0020190.
65. Reiling L, Richards JS, Fowkes FJ, Barry AE, Triglia T, Chokejindachai W, Michon P, Tavul L, Siba PM, Cowman AF, Mueller I, Beeson JG. 2010. Evidence that the erythrocyte invasion ligand PfRh2 is a target of protective immunity against Plasmodium falciparum malaria. J. Immunol. 185:6157-6167.
66. Stubbs J, Simpson KM, Triglia T, Plouffe D, Tonkin CJ, Duraisingh MT, Maier AG, Winzeler EA, Cowman AF. 2005. Molecular mechanism for switching of P. falciparum invasion pathways into human erythrocytes. Science 309:1384-1387.
67. Dutta S, Haynes JD, Barbosa A, Ware LA, Snavely JD, Moch JK, Thomas AW, Lanar DE. 2005. Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of Plasmodium falciparum. Infect. Immun. 73:2116-2122.
68. Arias-Bouda LM, Kuijper S, Van der Werf A, Nguyen LN, Jansen HM, Kolk AH. 2003. Changes in avidity and level of immunoglobulin G antibodies to Mycobacterium tuberculosis in sera of patients undergoing treatment for pulmonary tuberculosis. Clin. Diagn. Lab. Immunol. 10:702- 709.
69. Snounou G. 2002. Genotyping of Plasmodium spp. Nested PCR. Methods Mol. Med. 72:103-116.
70. Wooden J, Kyes S, Sibley CH. 1993. PCR and strain identification in Plasmodium falciparum. Parasitol. Today 9:303-305.
71. Ribacke U, Mok BW, Wirta V, Normark J, Lundeberg J, Kironde F, Egwang TG, Nilsson P, Wahlgren M. 2007. Genome wide gene amplifications and deletions in Plasmodium falciparum. Mol. Biochem. Parasitol. 155:33-44.
72. Gupta S SRW, Donnelly CA, Marsh K, Newbold C. 1999. Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat. Med. 5:340-343.
73. Osier FH, Fegan G, Polley SD, Murungi L, Verra F, Tetteh KK, Lowe B, Mwangi T, Bull PC, Thomas AW, Cavanagh DR, McBride JS, Lanar DE, MacKinnon MJ, Conway DJ, Marsh K. 2008. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect. Immun. 76:2240-2248.
74. Rovira-Vallbona E, Moncunill G, Bassat Q, Aguilar R, Machevo S, Puyol L, Quinto L, Menendez C, Chitnis CE, Alonso PL, Dobano C, Mayor A. 2012. Low antibodies against Plasmodium falciparum and imbalanced pro-inflammatory cytokines are associated with severe malaria in Mozambican children: a case-control study. Malar. J. 11:181. doi:10 .1186/1475-2875-11-181.
75. Voller A, Cornille-Brogger R, Storey J, Molineaux L. 1980. A longitudinal study of Plasmodium falciparum malaria in the West African savannah using the ELISA technique. Bull. World Health Organ. 58:429-438.
76. Greenhouse B, Ho B, Hubbard A, Njama-Meya D, Narum DL, Lanar DE, Dutta S, Rosenthal PJ, Dorsey G, John CC. 2011. Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic. J. Infect. Dis. 204:19-26.
77. Keh CE, Jha AR, Nzarubara B, Lanar DE, Dutta S, Theisen M, Rosenthal PJ, Dorsey G, Nixon DF, Greenhouse B. 2012. Associations between antibodies to a panel of Plasmodium falciparum specific antigens and response to sub-optimal antimalarial therapy in Kampala, Uganda. PLoS One 7:e52571. doi:10.1371/journal. pone.0052571.
78. Courtin D, Oesterholt M, Huismans H, Kusi K, Milet J, Badaut C, Gaye O, Roeffen W, Remarque EJ, Sauerwein R, Garcia A, Luty AJ. 2009. The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria. PLoS One 4:e7590. doi:10.1371/journal.pone.0007590.
79. Nair M, Hinds MG, Coley AM, Hodder AN, Foley M, Anders RF, Norton RS. 2002. Structure of domain III of the blood-stage malaria vaccine candidate, Plasmodium falciparum apical membrane antigen 1 (AMA1). J. Mol. Biol. 322:741-753.
80. Healer J, Murphy V, Hodder AN, Masciantonio R, Gemmill AW, Anders RF, Cowman AF, Batchelor A. 2004. Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody- mediated inhibition in Plasmodium falciparum. Mol. Microbiol. 52:159- 168.
81. Verra F, Hughes AL. 2000. Evidence for ancient balanced polymorphism at the apical membrane antigen-1 (AMA-1) locus of Plasmodium falciparum. Mol. Biochem. Parasitol. 105:149-153.
82. Kocken CH, van der Wel AM, Dubbeld MA, Narum DL, van de Rijke FM, van Gemert GJ, van der Linde X, Bannister LH, Janse C, Waters AP, Thomas AW. 1998. Precise timing of expression of a Plasmodium falciparum-derived transgene in Plasmodium berghei is a critical determinant of subsequent subcellular localization. J. Biol. Chem. 273:15119- 15124.
83. Narum D, Ogun S, Batchelor A, Holder A. 2006. Passive immunization with a multicomponent vaccine against conserved domains of apical membrane antigen 1 and 235-kilodalton rhoptry proteins protects mice against Plasmodium yoelii blood-stage challenge infection. Infect. Immun. 74:5529-5536.
84. Kusi KA FB, Thomas AW, Remarque EJ. 2009. Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity. PLoS One 4:e8110. doi:10.1371/journal.pone.0008110.
85. Fenton B, Clark JT, Wilson CF, McBride JS, Walliker D. 1989. Polymorphism of a 35-48 kDa Plasmodium falciparum merozoite surface antigen. Mol. Biochem. Parasitol. 34:79-86.
86. Thomas AW, Carr DA, Carter JM, Lyon JA. 1990. Sequence comparison of allelic forms of the Plasmodium falciparum merozoite surface antigen MSA2. Mol. Biochem. Parasitol. 43:211-220.
87. Mwingira F, Nkwengulila G, Schoepflin S, Sumari D, Beck HP, Snounou G, Felger I, Olliaro P, Mugittu K. 2011. Plasmodium falciparum msp1, msp2 and glurp allele frequency and diversity in sub-Saharan Africa. Malar. J. 10:79.
88. Peyerl-Hoffmann G, Jelinek T, Kilian A, Kabagambe G, Metzger WG, von Sonnenburg F. 2001. Genetic diversity of Plasmodium falciparum and its relationship to parasite density in an area with different malaria endemicities in West Uganda. Trop. Med. Int. Health 6:607-613.
89. Carlson J, Helmby H, Hill AV, Brewster D, Greenwood BM, Wahlgren M. 1990. Human cerebral malaria: association with erythrocyte rosetting and lack of anti-rosetting antibodies. Lancet 336:1457-1460.
90. Erunkulu OA, Hill AV, Kwiatkowski DP, Todd JE, Iqbal J, Berzins K, Riley EM, Greenwood BM. 1992. Severe malaria in Gambian children is not due to lack of previous exposure to malaria. Clin. Exp. Immunol. 89:296-300.
91. Tharavanij S, Warrell MJ, Tantivanich S, Tapchaisri P, Chongsa-Nguan M, Prasertsiriroj V, Patarapotikul J. 1984. Factors contributing to the development of cerebral malaria. I. Humoral immune responses. Am. J. Trop. Med. Hyg. 33:1-11.
92. Kohler C, Tebo AE, Dubois B, Deloron P, Kremsner PG, Luty AJ. 2003. Temporal variations in immune responses to conserved regions of Plasmodium falciparum merozoite surface proteins related to the severity of a prior malaria episode in Gabonese children. Trans. R. Soc. Trop. Med. Hyg. 97:455-461.
93. Guevara Patino JA, Holder AA, McBride JS, Blackman MJ. 1997. Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J. Exp. Med. 86:1689-1699.
94. Al-Yaman F, Genton B, Reeder JC, Mokela D, Anders RF, Alpers MP. 1997. Humoral response to defined Plasmodium falciparum antigens in cerebral and uncomplicated malaria and their relationship to parasite genotype. Am. J. Trop. Med. Hyg. 56:430-435.
95. Yang X, Adda CG, Keizer DW, Murphy VJ, Rizkalla MM, Perugini MA, Jackson DC, Anders RF, Norton RS. 2007. A partially structured region of a largely unstructured protein, Plasmodium falciparum merozoite surface protein 2 (MSP2), forms amyloid-like fibrils. J. Pept Sci. 13:839-848.
96. Iriemenam NC, Khirelsied AH, Nasr A, ElGhazali G, Giha HA, Elhassan A-Elgadir TM, Agab-Aldour AA, Montgomery SM, Anders RF, Theisen M, Troye-Blomberg M, Elbashir MI, Berzins K. 2009. Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan. Vaccine 27:62-71.
97. A-Elgadir TM, Elbashir MI, Berzins K, Masuadi EM, A-Elbasit IE, ElGhazali G, Giha HA. 2008. The profile of IgG-antibody response against merozoite surface proteins 1 and 2 in severe Plasmodium falciparum malaria in Eastern Sudan. Parasitol. Res. 102:401-409.
98. Persson KEM, Fowkes FJI, McCallum FJ, Gicheru N, Reiling L, Richards JS, Wilson DW, Lopaticki S, Cowman AF, Marsh K, Beeson JG. 2013. Erythrocyte-binding antigens of Plasmodium falciparum are targets of human inhibitory antibodies and function to evade naturally acquired immunity. J. Immunol. 191:785-794.
99. Mok BW, Ribacke U, Rasti N, Kironde F, Chen Q, Nilsson P, Wahlgren M. 2008. Default pathway of var2csa switching and translational repression in Plasmodium falciparum. PLoS One 3:e1982. doi:10.1371/journal .pone.0001982.